The Chinese firm ACROBiosystems, which is headquartered in Beijing, is to establish a presence at the Allschwil site of the Switzerland Innovation Park Basel Area. This is the biopharmaceutical firm’s first European subsidiary, while it already operates a site in Newark in the US State of Delaware.From the Basel Area, ACROBiosystems intends to expand its research and commercial activities across Europe, according to a statement. Both, the investment and innovation promotion agency Basel Area Business & Innovation and the foundation Switzerland Innovation, which brings innovative companies into contact with scientific institutions, supported ACROBiosystems in establishing its business in the area. “We welcome ACROBiosystems as a promising contributor to our vibrant life sciences community at the Switzerland Innovation Park Basel Area in Allschwil”, comments Karin Crisanto, Head Innovation Space and Infrastructure at Basel Area Business & Innovation, in the press release. She adds: “With its focus on collaboration with local customers and partners the company is a good fit for us”.
ACROBiosystems manufactures proteins, antibodies and other reagents for biopharmaceutical research. According to information from the company itself, by opening a new subsidiary, the aim is “to accelerate the growth of the company with our first active presence in Europe. The company supports academic and industrial clients working on target therapeutics, vaccines and diagnostics in all phases of product development. As CEO Mike Chen explains, ACROBiosystems is keen to foster better relationships with renowned universities, research institutions and hospitals in Switzerland with the ultimate aim of supporting “new product development to better understand and serve the biomedical field”.
The new location in the Basel Area is “exciting for us as it offers a valuable base for sales and marketing, better geographic coverage of our customers and collaborators and provides a foundation for our future plans of developing a facility for manufacturing, research and development to grow from”. Chen explains further in the statement.
